A Randomized, Participant- and Investigator-blinded, Placebo-controlled, Single Ascending Dose and Multiple Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of INE963 in Healthy Participants
Latest Information Update: 05 Oct 2023
At a glance
- Drugs INE 963 (Primary)
- Indications Malaria
- Focus Adverse reactions
- Sponsors Novartis Pharmaceuticals
- 26 Sep 2023 Status changed from completed to discontinued (Sponsor's decision).
- 25 Apr 2023 Status changed from discontinued to completed.
- 03 Feb 2023 Status changed from recruiting to discontinued.